Olmesartan, But Not Amlodipine, Improves Endothelium-Dependent Coronary Dilation in Hypertensive Patients

Naya, Masanao; Tsukamoto, Takahiro; Morita, Koichi; Katoh, Chietsugu; Furumoto, Tomoo; Fujii, Satoshi; Tamaki, Nagara; Tsutsui, Hiroyuki

doi:10.1016/j.jacc.2007.06.013

Cited by 99 publications

(60 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, we found that changes in pre-and post-heparin EC-SOD levels after olmesartan treatment were significantly and positively correlated with those in FMD, indicating the possibility that olmesartan may improve FMD by increasing EC-SOD to some degree, though these changes did not translate into overall changes in pre-and post-heparin EC-SOD levels. These observations are similar to those reported by Naya et al 36 who found that olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients and there was a significant correlation between the changes in endothelial function and SOD levels. Deterioration in renal function, namely chronic kidney disease, is associated with increased cardiovascular morbidity and mortality in the general population and various patient settings.…”

Section: Discussionsupporting

confidence: 92%

Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase

et al. 2011

View full text Add to dashboard Cite

Endothelial dysfunction in essential hypertension is an independent predictor for future cardiovascular events. Although inhibition of the renin-angiotensin system (RAS) reportedly improves endothelial function through its effects on oxidative stress and inflammation, questions remain regarding the factors that are pivotal for improvement of endothelial function by RAS inhibition. We therefore performed a prospective, randomized crossover trial in which an angiotensin II type 1 receptor antagonist, olmesartan and calcium channel blocker, amlodipine, were compared in 31 essential hypertensive patients. Results showed that, although both treatments achieved comparable lowering of blood pressure (BP), olmesartan, but not amlodipine, significantly improved endothelial function as evaluated by flow-mediated vasodilation (FMD) in the brachial artery. Although no significant changes in diabetic and lipid parameters were observed with either drug, olmesartan slightly decreased estimated glomerular filtration rate, which, surprisingly, translated into decreased microalbuminuria. In a similar vein, olmesartan reduced serum C-reactive protein and increased urine antioxidant levels compared with baseline, and reduced urine 8-epi-prostaglandin F2a levels compared with both baseline and amlodipine. Finally, although overall changes in plasma extracellular superoxide dismutase (EC-SOD) levels were not modulated by either treatment, for olmesartan there was a positive correlation between changes in FMD and those in EC-SOD levels. In conclusion, olmesartan improved endothelial function in hypertensive patients independent of its BP-lowering effect, which was due, at least in part, to its antioxidative property. Therefore, olmesartan might provide a greater long-term benefit for hypertensive patients with impaired endothelial function than amlodipine.

show abstract

Section: Discussionsupporting

confidence: 92%

Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase

et al. 2011

View full text Add to dashboard Cite

show abstract

“…These beneficial effects on coronary & forearm vasomotion might be via an antioxidant property of ARBs. [16,17] In this study, olmesartan an angiotensin receptor antagonist showed significant and consistent free radical scavenging activity by DPPH and Nitric oxide radical scavenging assays.Free radical scavenging activity of calcium channel blocker amlodipine was more significant than olmesartan but was inconsistent and non-concentration dependent.…”

Section: Discussionsupporting

confidence: 51%

Comparison of In vitro Antioxidant Activity of Olmesartan and Amlodipine

Thiruvengadam¹,

Sankar²

2016

IJPCS

View full text Add to dashboard Cite

Introduction: Free radical oxidative stress has been implicated in the pathology of a wide variety of clinical disorders. Antioxidants are agents which scavenge the free radicals and prevent the damage caused by them. Angiotensin II receptor blockers used in the treatment of hypertension, have also been reported to protect organs such as kidney and heart. Althoug, the mechanisms of these protective effects are not fully understood, it is generally thought that their antioxidant effects likely play a role. Amlodipine, a calcium channel blocker, seems to exert atheroprotective effects through its antioxidant properties related to its chemical structure and independent of its calcium channelblocking effect. Though research has proved that olmesartan and amlodipine exhibit antioxidant activity independent of their antihypertensive effects, there are not many in vitro studies to analyse which drug is a better antioxidant. Objective: This in vitro study was done to compare the antioxidant activity of olmesartan and amlodipine. Materials and Methods: In this study, we demonstrated the antioxidant activities of 10 mg/ml stock solutions of olmesartan and amlodipine in vitro. DPPH (1,1 Diphenyl 2-picryl hydrazide) and Nitric oxide free radical scavenging assays were done. Results: Olmesartan showed significant (49.48%) and consistent free radical scavenging activity by DPPH and Nitric oxide radical scavenging assays. Free radical scavenging activity of amlodipine was more significant (56.89%) than olmesartan but was inconsistent and non-concentration dependent. Conclusion: Hence this in vitro study has proved that olmesartan has better antioxidant activity than amlodipine.

show abstract

“…Participants were instructed to fast for > 6h, and to abstain from caffeine-containing products for > 24 hours prior to PET studies [4,[25][26]. Smokers were also instructed to refrain from smoking for >12h before the PET studies.…”

Section: Pet Acquisition Protocolmentioning

confidence: 99%

“…Coronary endothelial dysfunction is the earliest abnormality in the development of coronary atherosclerosis and is also independently associated with future cardiac events [2]. Several coronary risk factors adversely affect endothelial function [3][4][5][6]. Among these risk factors, smoking is the leading cause of preventable cardiovascular death and is a related factor in more than 450,000 deaths annually in the United States [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: comparison with 15O-labelled water PET

Yoshinaga

Manabe

Katoh

et al. 2010

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

show abstract

Olmesartan, But Not Amlodipine, Improves Endothelium-Dependent Coronary Dilation in Hypertensive Patients

Abstract: Olmesartan, but not amlodipine, improved endothelium-dependent coronary dilation in hypertensive patients independent of BP reduction. These beneficial effects on coronary vasomotion might be via an antioxidant property of ARBs.

Cited by 99 publications

References 16 publications

Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase

Olmesartan improves endothelial function in hypertensive patients: link with extracellular superoxide dismutase

Comparison of In vitro Antioxidant Activity of Olmesartan and Amlodipine

Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: comparison with 15O-labelled water PET

Contact Info

Product

Resources

About